Two large‐scale RCTs on newer classes of hypoglycemic agents, the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR‐Reduced) and the Dapagliflozin and Prevention of Adverse‐outcomes in Heart Failure trial (DAPA‐HF), confirmed the protective effects of SGLT‐2 inhibitors on cardiovascular function and renal outcomes.37, 38. Here, SLC5A2 is linked to heart failure.